Mediastinal Rosai-Dorfman Disease with KRAS mutation case report and literature review

Abstract

Background

Rosai-Dorfman Disease (RDD) is a rare self-limiting histiocytosis, more prevalent in children and young adults. It typically manifests as painless bilateral massive cervical lymphadenopathy but may also extend to extra-nodal sites, with intrathoracic RDD noted in 2% of cases. Distinguishing mediastinal RDD from thymoma on imaging poses challenges, underscoring the reliance on pathological features and immunohistochemical staining for diagnosis.

Case presentation

Patient, male, 33 years old, underwent lung a CT revealing an enlarged round soft tissue shadow in the anterior superior mediastinum, compared to a year ago. Surgical resection removed the entire mass, thymus, and part of the pericardium, confirming RDD on pathology. Genetic testing using second-generation testing technology identified a KRAS gene point mutation.

Conclusions

No established treatment protocol currently exists for this disease. However, as genetic mutation research progresses, a novel therapeutic avenue is emerging: targeted therapy integrated with surgical interventions.

Background

Rosai-Dorfman Disease (RDD), also recognized as sinus histiocytosis with massive lymphadenopathy, is a rare and self-limiting histiocytosis initially documented by Juan Rosai and Ronald Dorfman in 1969 [1]. Predominantly affecting children and young adults, RDD typically manifests as bilateral, massive, painless cervical lymphadenopathy. However, it can also extend to extra-nodal sites such as the skin, soft tissues, bones, upper respiratory tract, and ocular appendages, with only 2% of patients exhibiting intrathoracic RDD [2]. Notably, genetic test results for patients with mediastinal RDD remain unreported. Consequently, we present a unique case of mediastinal RDD and provide a comprehensive review of the clinical, pathological and genetic mutational characteristics associated with this disease.

Case presentation

Patient, male, 33 years old, admitted with a mediastinal mass identified during lung computed tomography (CT). Notably, the patient had previously undergone the excision of a right retroperitoneal mass in our hospital a year ago, with postoperative pathology suggesting paraganglioma. The patient’s medical history was otherwise unremarkable. One year before admission, the patient’s lung CT revealed a round-like soft tissue density shadow in the anterior superior mediastinal thymus area, characterized by clear margins and uniform density. At that time, it had a maximum diameter of 2.1*2.7 cm and a CT value of approximately 41 Hounsfield units (HU). The mass was observed to be attached to the pericardium, with limited pericardial thickening evident (Fig. 1A). However, a subsequent lung CT post-admission revealed a substantial enlargement of the mass, with a maximum diameter measuring 5.3*2.2 cm (Fig. 1B). The patient reported weakness but denied other symptoms, including fever, night sweats, and weight loss throughout the disease course. Initially diagnosed as thymoma, surgical intervention was performed to remove the entire mass, thymus, and a portion of the pericardium. Subsequent pathological examination of the excised tissue was conducted.

Fig. 1

A The patient’s chest CT one year before admission, the size of the lesion was about 2.1*2.7 cm; B The patient’s arterial stage of chest enhancement CT on admission, with a lesion size approximately 5.3*2.2 cm; C The patient’s 3-month postoperative chest CT; D The patient’s 9-month postoperative chest CT; E The patient’s 2-year postoperative chest CT

Hematoxylin and eosin (H&E) staining at low magnification exhibited an alternating distribution of bright and dark bands (Fig. 2A). Upon high magnification, cytoplasm-rich histiocytes with a significant infiltration of lymphocytes and plasma cells at the periphery were evident, along with the characteristic feature of emperipolesis, indicative of RDD (Fig. 2B). Immunohistochemical analysis revealed positive expression of S-100 and CD68 in the tissue cells, while CD1a was conspicuously absent (Fig. 2C, D, E). The ultimate pathological diagnosis established RDD. Patients also underwent comprehensive genetic testing, encompassing “tumor targeted drugs + chemotherapy drugs + immunogenetic testing 1021,” utilizing second-generation detection technology. This encompassed the assessment of four mutations within 1,021 genes associated with tumor development, including point mutations, small indels, copy number variations, and known fusion genes. The findings unveiled a point mutation in KRAS, specifically c.437C > T (p.A146V).

Fig. 2

A Alternating bright and dark bands were seen under low magnification (HE 100x).; B High magnification reveals cytoplasm-rich histiocytes with more lymphocytes and plasma cells infiltrating the periphery; the emperipolesis is visible (HE 400x); C Histocyte S-100 positive with visible emperipolesis (IHC 400x); D CD68 positive (IHC 400x); E CD1a negative (IHC 400x)

Following a 5-day observation period, the patient was discharged without encountering any complications. Subsequent to discharge, we maintained a scheduled follow-up regimen. Over the course of this follow-up, the patient underwent three repeat lung CT examinations, and the results revealed no discernible evidence of recurrence (Fig. 1C, D, E).

Discussion and literature review

RDD is a rare histiocytosis, previously categorized as a non-Langerhans cell histiocytosis. However, in the latest classification by the Histoplasmosis Society, cutaneous RDD is now designated within the histiocytosis group C, while other forms of RDD are categorized under the R group of histiocytosis [3].

The prevalence of RDD is notably low, estimated at 1:200,000. Approximately 43% of patients manifest extra-nodal lesions, and intrathoracic involvement is observed in merely about 2% of patients [2]. Specifically, mediastinal RDD accounts for a strikingly minimal proportion, constituting only 0.5% or less of all mediastinal space-occupying lesion [4]. Employing the PubMed database and utilizing the search formula “((thoracic) OR (mediastinal)) AND ((Rosai-Dorfman disease) OR (Sinus histiocytosis with massive lymphadenopathy))”, we conducted a comprehensive search without restricting the time frame. This yielded 142 documents, and subsequent scrutiny in accordance with the PRISMA (Preferred Reporting Items for Systematic Evaluation and Meta-Analysis) guidelines revealed a total of 23 case reports [4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26], documenting 23 patients diagnosed with mediastinal RDD (Table 1).

Table 1 Summary of findings in mediastinal Rosai–Dorfman Disease patient

CT/MRI plain images of RDD-afflicted patients typically reveal well-defined, irregularly shaped lesions characterized by uniform densities/signals and significantly progressive enhancements on multi-contrast enhancement imaging [27]. All included patients underwent lung CT or enhanced lung CT before biopsy, yielding varying imaging descriptions. Importantly, none received a pre-biopsy RDD diagnosis, and clinicians primarily considered differential diagnoses such as lymphoma, benign and malignant thymic tumors, pulmonary artery embolism, or noninfectious inflammatory disease [13]. This underscores the challenge in leveraging lung CT results for definitive diagnoses, emphasizing their role more in disease screening and guiding the surgical approaches. PET-CT may offer improved insights into RDD indications. In a study by Jia et al. [11], a patient with anterior mediastinal RDD exhibited abnormally high FDG uptake (SUVmax 8.96) on PET/CT, surpassing the average metabolic activity of thymic hyperplasia (SUVmax 1.1), thymoma (SUVmax 2.3) and thymic carcinoma (SUVmax 7.0) [28]. Notably, two reports by Agarwal et al. [6] and Furia et al. [21] recorded even higher SUVmax values at 34.0 and 35.0, indicating a potential reference value for PET-CT in RDD diagnosis.

A definitive diagnosis of RDD typically necessitates HE staining and immunohistochemical analysis. Regardless of the location, RDD is pathologically characterized by sinusoidal hyperplasia of large histiocytes, with extra-nodal lesions often exhibiting a more prominent fibrotic component. Furthermore, in late-stage RDD lesions, fibrosis becomes more prevalent, making the identification of residual RDD islands challenging [29]. While emperipolesis is a crucial indicator suggesting RDD disease, it is not entirely specific, as scattered emperipolesis can be observed in other histiocytic disorders such as Erdheim-Chester disease, yellow granuloma and malignant histiocytosis [30,31,32]. Meanwhile, immunohistochemistry plays a pivotal role in further delineating RDD disease. The immunophenotype of RDD cells typically manifests as positive for S-100 and CD68, with the potential for positivity in CD163 and CD14. Notably, CD1a is usually negative, serving as a point of differentiation from Langerhans cell histiocytosis [2]. Among all the mediastinal RDD cases included in our study, only one case encountered challenges in obtaining a biopsy sample through surgical resection or puncture. However, histiocytes were observed in all completed pathologies, and immunohistochemistry demonstrated positive results for at least one of S-100 or CD68.

The pathogenesis of RDD remains unclear, with some studies suggesting a potential association with viral infections such as herpesvirus, Epstein-Barr virus, cytomegalovirus, and HIV, but a definitive link has yet to be established [33]. More recently, investigations have revealed mutations in NRAS, KRAS, MAP2K1, and ARAF in RDD cases [34,35,36,37,38]. Among the mediastinal RDD cases included in our study, one patient’s mediastinal sample underwent whole exome sequencing, identifying a missense variant in the IRF5 gene [7]. Another patient showed the presence of a KRAS gene mutation, as identified by next-generation sequencing [13]. Additionally, Lee et al. reported a RDD case with the same KRAS gene mutation (p.A146V), although the lesion’s location in this patient was not explicitly documented [37]. In our study, patients underwent genetic testing utilizing next-generation sequencing technology, revealing mutations in the KRAS gene [NM_033360.2: c.437C > T (p.A146V)] at a frequency of 2.4%. The detection technology employed encompassed four mutation types, including point mutations, small indels, copy number variations, and known fusion genes. The average effective sequencing depth was 1714, covering 1021 genes associated with tumorigenesis and development. The testing strategy included the examination of all exon regions of 312 genes, introns, promoters, or fusion breakpoint regions of 38 genes, and partial exons of 709 genes for somatic mutations. Additionally, all exons of 39 genes were scrutinized for germline mutations, along with assessments for tumor mutational burden and microsatellite instability. Remarkably, our case represents the second instance of identifying KRAS gene mutations in mediastinal RDD, offering potential new insights into the etiology of this condition.

There are currently no established standard treatment protocols for mediastinal RDD. Given its often self-limiting nature, conservative management is deemed acceptable. However, among our included cases, surgical resection was undertaken in 21 out of 23 patients for symptomatic relief or definitive diagnosis. The beneficial effects of corticosteroid therapy and radiotherapy were also evident, as reported by Furia et al. [21]. A pivotal study by Garces et al. highlighted that activating mutations in RAS/RAF/MAPK/ERK or related signaling pathways may play a role in RDD development [36]. This implies that post-operative genomic analysis and targeted therapy administration could potentially improve outcomes for these patients.

Conclusion

We documented a case of mediastinal RDD with KRAS mutations, exhibiting imaging, pathological, and immunohistochemical features consistent with the characteristics observed in extra-nodal lesions of RDD.